Skip to main content
. Author manuscript; available in PMC: 2019 Apr 25.
Published in final edited form as: Semin Hematol. 2018 Apr 25;55(2):87–93. doi: 10.1053/j.seminhematol.2018.04.011

Table 2.

Reduced or Low Intensity Conditioning HCT for SCD

Authors N Median Age (years) Conditioning OS Graft Rejection DFS cGVHD TRM
King et al (2015) 43 13 Flu-Mel- Alemtuzumab 93% <2% 91% @ 3 years 13% 7%
Hsieh et al (2014) and updated 52 29 TBI (300 cGy)- Alemtuzumab 94% 11.5% 88.5% 0% 0%
Saraf et al (2016) 13 30 TBI (300 cGy)- Alemtuzumab 100% 8% 92% 0% 0%
Ozdogu et al (2018) 20 33 Flu - Bu - Cy - ATG - TBI (200 cGy) 100% 0% 100% 0% 0%

OS, overall survival; DFS, disease-free survival; cGVHD, chronic graft-versus-host disease; TRM, transplant-related mortality; Flu, fludarabine; Mel, melphalan; TBI, total body irradiation; Bu, busulfan; Cy, cyclophosphamide; ATG, anti-thymocyte globulin